Cipla Limited has informed the Exchange about USFDA inspection at Company's manufacturing facility in Goa, India
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The USFDA inspected Cipla's manufacturing plant in Verna, Goa from April 6 to April 17, 2026. The inspection covered both routine cGMP compliance and a Pre-Approval Inspection (PAI) for new product approvals. At the end of the inspection, Cipla received a Form 483 with 2 observations. The company has stated it will work with the USFDA to address these observations within the stipulated timeframe. No warning letter or import alert has been issued. The Goa facility is one of Cipla's key manufacturing sites supplying medicines to the US market.
A Form 483 with only 2 minor observations is relatively benign for a pharma company and the stock is unlikely to see a sharp negative reaction. However, since the inspection also included a Pre-Approval Inspection, the outcome could influence the timeline for certain pending US product approvals. Investors should watch for further updates on whether the observations are resolved without escalation.